Rising Leaders
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
It has been quite a year for German biotech Tubulis, and CEO Dominik Schumacher tells In Vivo that the group has the potential to be “a really meaningful, sizable leader” in the antibody-drug conjugate space.
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.
Tuyen Ong, a CEO-partner at Flagship Pioneering and CEO of Ring Therapeutics, discusses the importance of balancing short-term wins with a longer-term vision when building a biotech.
“I'm a strong believer in creating the right mix between young ambitious people and pairing them up with someone experienced,” says Jeroen Bakker, who is focused on biotech company creation at Seed Investments, Novo Holdings.
2024 In Vivo Rising Leader Somer Baburek wants to overhaul how endometriosis is diagnosed and managed with a product that she says has billion-dollar potential.
Laksh Aithani, CEO of CHARM Therapeutics, discusses key challenges for the flourishing AI drug development sector including finding the right people and the need for more success stories.
Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.
Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.
Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.
AI Medical Technology has been busy, with publications demonstrating its lead product’s potential in melanoma, ongoing fundraising and board appointments.
Having raised $345m in an IPO last year, prior to entering the clinic, Apogee Therapeutics has emerged as a startup to watch. Chief medical officer Carl Dambkowski, one of In Vivo’s 2024 Rising Leaders, shares more about the biotech’s pipeline strategy.
Laura Soucek, a former In Vivo Rising Leader, and her co-founder have built their biotech, Peptomyc, around a previously undruggable target. They spoke about successes and learnings as scientist-entrepreneurs at BioEurope Spring.
Leveraging the biotech entrepreneurial spirit and global pharma resources is a win-win situation in the race to bring meaningful medicines to patients.
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
One of In Vivo's 2024 Rising Leaders, Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company's lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.
With an engineer’s mind, Jason Park, CEO of Empress Therapeutics, has a unique take on problem solving for fundraising and the value of being a platform company focused on small molecules.
Addie MacGregor, at the Association of British HealthTech Industries, guides and advises an industry eager to comply but in search of direction, on matters of environmental sustainability for health care technology manufacturers.
Success in life sciences venture funding requires drive and speed, says In Vivo Rising Leader, Clare Terlouw. But there is more to it than that.
ADVERTISEMENT